Matthew Stanton, CFA
Stock Analyst at Jefferies
(1.05)
# 3,880
Out of 4,639 analysts
22
Total ratings
57.1%
Success rate
-5.1%
Average return
Main Sectors:
Stocks Rated by Matthew Stanton, CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Downgraded: Hold | $22 → $31 | $34.64 | -10.51% | 2 | Jul 23, 2026 | |
| CYRX Cryoport | Maintained: Hold | $9.5 → $13 | $14.82 | -12.28% | 6 | Jun 8, 2026 | |
| RGEN Repligen | Maintained: Hold | $135 → $142 | $163.17 | -12.97% | 7 | May 5, 2026 | |
| AZTA Azenta | Maintained: Buy | $42 → $35 | $33.33 | +5.01% | 5 | Apr 1, 2026 | |
| MRVI Maravai LifeSciences Holdings | Maintained: Buy | $10 | $6.07 | n/a | 1 | Mar 18, 2025 | |
| LAB Standard BioTools | Initiated Coverage: Buy | $3.25 | $0.7888 | n/a | 1 | Apr 4, 2024 |
BioLife Solutions
Jul 23, 2026
Downgraded: Hold
Price Target: $22 → $31
Current: $34.64
Upside: -10.51%
Cryoport
Jun 8, 2026
Maintained: Hold
Price Target: $9.5 → $13
Current: $14.82
Upside: -12.28%
Repligen
May 5, 2026
Maintained: Hold
Price Target: $135 → $142
Current: $163.17
Upside: -12.97%
Azenta
Apr 1, 2026
Maintained: Buy
Price Target: $42 → $35
Current: $33.33
Upside: +5.01%
Maravai LifeSciences Holdings
Mar 18, 2025
Maintained: Buy
Price Target: $10
Current: $6.07
Upside: n/a
Standard BioTools
Apr 4, 2024
Initiated Coverage: Buy
Price Target: $3.25
Current: $0.7888
Upside: n/a